# OnCo record deutenzalutamide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/deutenzalutamide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "deutenzalutamide" ;
  schema:name "Deutenzalutamide"@en ;
  schema:alternateName "HC-1119"@en, "HC1119"@en, "海纳安"@en, "氘恩扎鲁胺软胶囊"@en ;
  schema:description "Deutenzalutamide is a hormone-blocking capsule from Hinova Pharmaceuticals, a modified form of enzalutamide, approved in China in 2025 for prostate cancer that has spread and stopped responding to hormone therapy."@en ;
  schema:url <https://onco.cc/drugs/deutenzalutamide/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.hinovapharma.com/en/chanpinxianguan.html>, <https://www.hinovapharma.com/en/chanpinxianguan.html>, <https://www.hinovapharma.com/chanpinxianguan.html>, <https://clinicaltrials.gov/search?intr=HC-1119> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule (oral soft capsule), deuterated androgen receptor antagonist" ;
  onco:approval "China 2025: Metastatic castration-resistant prostate cancer" ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:targets <https://onco.cc/targets/androgen-receptor/> ;
  onco:companies <https://onco.cc/companies/hinova-pharmaceuticals/> ;
  onco:trials <https://onco.cc/trials/nct03851640/>, <https://onco.cc/trials/nct03850795/>, <https://onco.cc/trials/nct03774056/>, <https://onco.cc/trials/nct03778047/>, <https://onco.cc/trials/nct03776968/> .